Nattokinase: The Enzyme That Shrinks Arterial Plaque

🧬 Origin & Classification

Nattokinase is a serine protease enzyme produced by the bacterium Bacillus subtilis (specifically B. subtilis var. natto) during the fermentation of soybeans into natto — a traditional Japanese food consumed for over 1,000 years. The enzyme is formally classified as subtilisin NAT, a member of the subtilisin family of proteases.

It was first identified and characterized by Dr. Hiroyuki Sumi in 1987 while researching thrombolytic enzymes at the University of Chicago. Dr. Sumi tested over 170 foods for fibrinolytic activity before discovering that natto contained the most potent natural clot-dissolving compound he had ever measured.

Nattokinase is a 275-amino-acid protein with a molecular weight of approximately 27.7 kDa. What makes it exceptional among dietary enzymes is its ability to survive gastric transit and remain biologically active in the bloodstream — a property many oral enzymes lack.

🇯🇵 Traditional Use & Epidemiological Context

Natto has been a staple of the Japanese diet — particularly in eastern Japan — for centuries. Japan has one of the lowest rates of cardiovascular disease globally, and epidemiological studies have noted an association between natto consumption and reduced cardiovascular mortality. A prospective cohort study following 29,079 Japanese adults for 16 years (published in the American Journal of Clinical Nutrition, 2017) found that higher natto intake was significantly associated with reduced risk of cardiovascular mortality.

While correlation doesn't prove causation (the Japanese diet has many cardioprotective elements), the consistency of this association across multiple studies prompted clinical investigation into isolated nattokinase supplementation.

📋 Regulatory Status

Nattokinase is classified as a dietary supplement in the United States and is not FDA-approved as a drug for treating or preventing any disease. It is available over the counter and generally recognized as safe (GRAS) in food-derived forms. In Japan, it is classified as a functional food ingredient. The Japan Nattokinase Association (JNKA) certifies quality standards for nattokinase supplements.

📊 Study Overview: n=1,062

The most significant nattokinase study to date enrolled 1,062 participants and measured changes in carotid artery intima-media thickness (CIMT) and atherosclerotic plaque size over a 12-month supplementation period. CIMT is a validated surrogate marker for systemic atherosclerosis — thicker arterial walls and larger plaques correlate with higher cardiovascular event risk.

Participants received nattokinase supplementation alongside standard care. After 12 months, the nattokinase group showed a 36.6% reduction in plaque size as measured by carotid ultrasound. This is a remarkable result — most interventions that show any plaque regression at all require high-dose statins or PCSK9 inhibitors.

Key limitation — This study should be interpreted with appropriate scientific caution. Not all studies of this design have been double-blinded, and lifestyle co-interventions may have contributed. Replication in large randomized controlled trials is needed before drawing definitive causal conclusions.

📈 Plaque Study Results — Key Metrics

Progress bars represent relative magnitude for visual comparison. Plaque reduction bar scaled to show significance relative to 50% maximum.

🔍 Supporting Plaque Evidence

An earlier study published in Atherosclerosis (2009) examined 82 patients over 26 weeks. Participants taking 6,000 FU/day of nattokinase showed a significant reduction in carotid plaque size compared to statin therapy alone. While smaller, this study used a randomized controlled design and found nattokinase comparable to statin monotherapy for plaque regression.

A 2022 systematic review in Frontiers in Cardiovascular Medicine pooled data from multiple nattokinase trials and concluded there was "moderate evidence" supporting its antiatherosclerotic properties, while calling for larger RCTs to establish clinical guidelines.

📉 Clinical Blood Pressure Data

A randomized, double-blind, placebo-controlled trial published in Hypertension Research (2008) enrolled 86 participants with borderline or mild hypertension. After 8 weeks of nattokinase supplementation (2,000 FU/day), the treatment group showed:

These reductions are clinically meaningful. A 5 mmHg systolic reduction is associated with approximately a 10% reduction in cardiovascular event risk at a population level (Lancet, 2002). While modest compared to prescription antihypertensives, this effect is notable for a dietary supplement.

🔬 Mechanism: Natural ACE Inhibition

Nattokinase inhibits angiotensin-converting enzyme (ACE) in a similar mechanism to pharmaceutical ACE inhibitors (enalapril, lisinopril, ramipril). However, nattokinase's ACE inhibition is considerably weaker than prescription medications — it should be viewed as a complementary approach, not a replacement for prescribed antihypertensives.

A 2016 study in the International Journal of Molecular Sciences confirmed nattokinase's ACE-inhibitory peptides and noted additional vasodilatory effects through prostaglandin pathways, suggesting the blood pressure reduction involves multiple mechanisms beyond ACE inhibition alone.

✈️ Deep Vein Thrombosis (DVT) Prevention

A notable randomized controlled trial published in Angiology (2003) studied DVT risk in long-haul air travelers — a population at elevated thrombotic risk due to prolonged immobility. The study enrolled 204 participants on flights exceeding 7 hours.

The nattokinase group showed significantly lower D-dimer levels (a marker of clot formation and breakdown) and no DVT events, compared to a higher incidence in controls. While the study was relatively small, it provided mechanistic confirmation that oral nattokinase reaches the bloodstream in active form and exerts measurable antithrombotic effects.

🧠 Stroke Prevention & Neuroprotection

Approximately 87% of all strokes are ischemic — caused by blood clots blocking cerebral arteries. By reducing clot formation (anti-platelet activity) and enhancing clot dissolution (fibrinolysis), nattokinase addresses two of the core mechanisms of ischemic stroke.

Animal studies have demonstrated that nattokinase administration reduced infarct volume (area of brain tissue death) in experimental stroke models. While direct human stroke prevention data is limited, the aggregate of its anti-thrombotic, blood pressure-lowering, and anti-inflammatory effects supports a cardio-cerebrovascular protective profile.

This neuroprotective angle is particularly relevant to anyone building a brain protection stack. Nattokinase pairs well with omega-3 fatty acids, which reduce neuroinflammation, and compounds like lion's mane that support nerve growth factor production. See our Anti-Dementia Stack guide for a complete protocol.

💊 Nattokinase vs. Pharmaceutical Blood Thinners

Educational comparison only — NOT a recommendation to substitute

Nattokinase is sometimes compared to prescription anticoagulants like warfarin, aspirin, or clopidogrel. Here's how they differ:

Warfarin works by inhibiting vitamin K-dependent clotting factors (II, VII, IX, X). It prevents new clot formation but doesn't dissolve existing clots. Nattokinase both prevents new clots AND dissolves existing fibrin.

Aspirin irreversibly inhibits COX-1 in platelets, reducing thromboxane A2 and platelet aggregation. Nattokinase achieves similar anti-platelet effects through a different mechanism.

However, pharmaceutical anticoagulants are far more potent and predictable than nattokinase. They are prescribed for specific clinical indications (atrial fibrillation, mechanical heart valves, post-surgical prophylaxis) where consistent, dose-controlled anticoagulation is critical. Nattokinase has not been validated as a substitute for prescription anticoagulants in these high-risk scenarios.

🤝 Can You Take Both?

Many supplements combine nattokinase + serrapeptase in a single product ("systemic enzyme" formulas). The rationale is complementary mechanisms: nattokinase for clot dissolution and cardiovascular protection, serrapeptase for inflammation and tissue debris clearance.

While this combination is widely used, there is limited clinical data on the specific combination. The theoretical basis is sound, but if you're taking blood thinners, the combined anti-platelet effects require extra caution. As always, consult a physician before stacking proteolytic enzymes with anticoagulant medications.

📐 Understanding FU (Fibrinolytic Units)

Nattokinase potency is measured in FU — fibrinolytic units. This measures the enzyme's actual biological activity (how much fibrin it can dissolve), not just the weight of the powder. This is similar to how other enzymes are standardized by activity rather than mass.

1 FU = the amount of nattokinase needed to generate 1 µg of plasmin activity under standardized assay conditions. The Japan Nattokinase Association (JNKA) has established testing protocols to ensure consistent FU measurement across products.

When buying nattokinase, always check the FU count, not just the milligram weight. A 100mg capsule with 2,000 FU is more potent than a 200mg capsule with 1,000 FU. The activity is what matters.

🧮 Quick Reference

Standard dose: 2,000 FU/day   Upper range: 4,000 FU/day   Empty stomach for absorption

Need help calculating your stack doses? Try our Dosing Calculator.

Additional Safety Considerations

• Bleeding disorders: Nattokinase is contraindicated in people with hemophilia, von Willebrand disease, or other bleeding disorders. The enzyme's fibrinolytic activity poses unacceptable risk.
• Pregnancy & breastfeeding: Insufficient safety data. Avoid nattokinase during pregnancy and lactation unless specifically directed by a physician.
• Low blood pressure: Nattokinase's ACE-inhibiting and vasodilatory effects may cause excessive blood pressure drops in people with already-low BP. Monitor symptoms (dizziness, lightheadedness).
• GI upset: Some users report mild nausea, diarrhea, or stomach discomfort — typically transient and dose-related. Starting with a lower dose and titrating up may help.
• Soy allergy: Nattokinase is derived from soy fermentation. While the enzyme itself is highly purified, trace soy proteins may be present. Individuals with severe soy allergies should exercise caution or choose soy-free formulations (some manufacturers produce nattokinase via non-soy fermentation substrates).